PMID- 1356579
OWN - NLM
STAT- MEDLINE
DCOM- 19921026
LR  - 20190613
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 581
IP  - 2
DP  - 1992 May 29
TI  - Methamphetamine neurotoxicity and striatal glutamate release: comparison to 
      3,4-methylenedioxymethamphetamine.
PG  - 237-43
AB  - The effect of repeated administration of either methamphetamine (MA), 
      3,4-methylenedioxymethamphetamine (MDMA) or vehicle on the extracellular 
      concentrations of glutamate (GLU), aspartate, taurine, dopamine (DA) and its 
      metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), was studied in awake, freely 
      moving rats using in vivo microdialysis. MA (7.5 mg/kg, i.p.) administered every 
      2 h for a total of 3 injections, increased the extracellular concentration of GLU 
      in the anteromedial striatum. By contrast, neither vehicle nor MDMA (9.2 and 13.8 
      mg/kg) increased GLU efflux following repeated administration. Both MA and MDMA 
      increased the extracellular concentration of DA in the striatum. However, the 
      cumulative increase in DA was significantly greater in the MDMA treated animals 
      as compared to the MA group. The concentrations of DA, serotonin (5-HT) and their 
      metabolites were determined in the striatum 7 days following the repeated 
      administration of MA, MDMA and vehicle. MA, but not MDMA or vehicle, decreased 
      the concentration of DA in the striatum. Conversely, MDMA (13.8 mg/kg) decreased 
      the concentration of 5-HT, whereas MA, MDMA (9.2 mg/kg) and vehicle had no effect 
      on striatal 5-HT content. These data are suggestive that the long-term (7 day) DA 
      neurotoxicity produced by the repeated administration of MA is mediated, in part, 
      by a delayed increase in extracellular concentrations of GLU. In contrast, 
      repeated administration of MDMA, at a dose which produced a long-term (7 day) 
      depletion of striatal 5-HT content, had no effect on GLU efflux in the striatum.
FAU - Nash, J F
AU  - Nash JF
AD  - Department of Psychiatry, School of Medicine, Case Western Reserve University, 
      Cleveland, OH 44106-5000.
FAU - Yamamoto, B K
AU  - Yamamoto BK
LA  - eng
GR  - DA06491/DA/NIDA NIH HHS/United States
GR  - MH 41684/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Designer Drugs)
RN  - 0 (Glutamates)
RN  - 0 (Neurotoxins)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 1EQV5MLY3D (Taurine)
RN  - 30KYC7MIAI (Aspartic Acid)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/toxicity
MH  - Analysis of Variance
MH  - Animals
MH  - Aspartic Acid/metabolism
MH  - Corpus Striatum/drug effects/*metabolism/pathology
MH  - Designer Drugs
MH  - Dialysis/methods
MH  - Dopamine/metabolism
MH  - Glutamates/*metabolism
MH  - Kinetics
MH  - Male
MH  - Methamphetamine/*toxicity
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Neurotoxins/*toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Reference Values
MH  - Taurine/metabolism
MH  - Time Factors
EDAT- 1992/05/29 00:00
MHDA- 1992/05/29 00:01
CRDT- 1992/05/29 00:00
PHST- 1992/05/29 00:00 [pubmed]
PHST- 1992/05/29 00:01 [medline]
PHST- 1992/05/29 00:00 [entrez]
AID - 0006-8993(92)90713-J [pii]
AID - 10.1016/0006-8993(92)90713-j [doi]
PST - ppublish
SO  - Brain Res. 1992 May 29;581(2):237-43. doi: 10.1016/0006-8993(92)90713-j.